RATHL
Showed that patients whose PET scan is clear after two cycles can safely drop bleomycin and its lung toxicity.
PET2-negative patients randomised to ABVD or AVD: 3-year PFS 85.7% vs 84.4% (difference within non-inferiority margin), with fewer pulmonary events; PET2-positive escalated to BEACOPP with 3-year PFS 67.5%. Established interim PET as a treatment-steering tool.
- 85.7 vs 84.4 out of 100 alive without the cancer growing at 3 years with ABVD compared with AVD; 1.3 more per 100.
- Roughly one extra person helped for every 77 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Advanced Hodgkin lymphoma: interim-PET-guided omission of bleomycin (AVD) vs continued ABVD. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,214 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival at 3 years (PET2-negative)primary | ABVD | 470 | 85.7% | — | — | link |
| AVD | 465 | 84.4% |
Pages like this
not linked directly; found by shared links- TrialECHELON-1
Shares Caution: bleomycin lung toxicity, especially with brentuximab or G-CSF, Hodgkin lymphoma.
- TrialAHOD2131 (COG / NCTN)
Shares PET-adapted (response-adapted) therapy, Hodgkin lymphoma.
- InstitutionUniversity Hospital Southampton / Centre for Cancer Immunology
Shares FDG PET, Hodgkin lymphoma, Cancer Research UK.
- TermLugano classification / Ann Arbor staging
Shares FDG PET, Hodgkin lymphoma.
- IdeaChemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage
Shares PET-adapted (response-adapted) therapy, Hodgkin lymphoma.
- TrialGHSG HD21
Shares PET-adapted (response-adapted) therapy, Hodgkin lymphoma.
- InstitutionGerman Hodgkin Study Group
Shares FDG PET, Hodgkin lymphoma.
- TermDeauville score and PET-adapted therapy
Shares FDG PET, Hodgkin lymphoma.